WuXi AppTec Co., Ltd. (HKG:2359)

Market Cap	328.64B
Revenue (ttm)	45.91B
Net Income (ttm)	15.09B
Shares Out	n/a
EPS (ttm)	4.37
PE Ratio	21.78
Forward PE	21.63
Dividend	1.43 (1.42%)
Ex-Dividend Date	May 15, 2025

Volume	11,624,202
Average Volume	9,762,653
Open	102.00
Previous Close	101.30
Day's Range	101.00 - 108.80
52-Week Range	32.10 - 116.50
Beta	0.73
RSI	60.81
Earnings Date	Oct 27, 2025

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 39,414
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2359

Financial Performance

In 2024, WuXi AppTec's revenue was 37.92 billion, a decrease of -1.97% compared to the previous year's 38.68 billion. Earnings were 9.45 billion, a decrease of -1.63%.

Financial numbers in CNY